FDA Drug recall D-1613-2014
Black Ant, 2800 mg, four capsules per box, Manufacturer Qinghai Baojiantang Pharmaceutical Co., Ltd
- FDA Drug
- Class I
- terminated
- Published 2014-10-08
On 2014-10-08 the FDA classified a Class I recall of Black Ant, 2800 mg, four capsules per box, Manufacturer Qinghai Baojiantang Pharmaceutical Co., Ltd by Eugene Oregon, citing marketed Without an Approved NDA/ANDA: Eugene FDA laboratory analyses determined they contain undeclared sildenafil.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-1613-2014 |
| Classification | Class I |
| Status | terminated |
| Initiated | 2014-05-05 |
| Published | 2014-10-08 |
| Last updated | 2026-09-13 11:51 UTC |
| Company | Eugene Oregon |
| Distribution | FL, IL, IN, LA, MD, ME, NJ, PA, SC, TX, WA |
Product
Black Ant, 2800 mg, four capsules per box, Manufacturer Qinghai Baojiantang Pharmaceutical Co., Ltd.
Reason
Marketed Without an Approved NDA/ANDA: Eugene FDA laboratory analyses determined they contain undeclared sildenafil.
Identifiers
| code_info | All lots |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:51 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1613-2014%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.